The startup develops diagnostic products utilizing immune and molecular methodologies for the early detection of lung cancer, tuberculosis, and myocardial inflammation. Their technology enables timely diagnosis, which is critical for improving patient outcomes and treatment efficacy.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic methods for lung cancer, tuberculosis, and myocardial inflammation often lack the sensitivity and speed required for early detection. Delayed diagnoses can lead to poorer patient outcomes and reduced treatment effectiveness.
Solution
The startup develops diagnostic products leveraging both immune and molecular methodologies to enable earlier and more accurate detection of lung cancer, tuberculosis, and myocardial inflammation. By combining these approaches, the company aims to improve diagnostic sensitivity and specificity, leading to earlier interventions and improved patient outcomes. The technology is designed to provide clinicians with actionable insights at critical decision points in patient care.
Target Audience
The primary target audience includes hospitals, diagnostic laboratories, pulmonologists, cardiologists, and oncologists seeking advanced diagnostic tools for early disease detection and improved patient management.
Features
- Immunoassay-based diagnostics for rapid detection of disease biomarkers
- Molecular diagnostic assays utilizing PCR and next-generation sequencing for high-sensitivity pathogen detection and disease characterization
- Multiplex assays capable of simultaneously detecting multiple biomarkers or pathogens
- Automated sample processing and analysis to minimize human error and improve turnaround time
- Cloud-based data analytics platform for secure storage, analysis, and reporting of diagnostic results